BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu JI, Park HC. Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2016; 22(30): 6851-6863 [PMID: 27570422 DOI: 10.3748/wjg.v22.i30.6851] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Huang Y, Lu Y, Lu S. Sequential bilateral PVTT successfully controlled by radiotherapy and sorafenib, respectively. Kaohsiung J Med Sci 2019;35:63-4. [DOI: 10.1016/j.kjms.2018.06.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
2 Thompson SM, Wells ML, Andrews JC, Ehman EC, Menias CO, Hallemeier CL, Roberts LR, Venkatesh SK. Venous invasion by hepatic tumors: imaging appearance and implications for management. Abdom Radiol (NY) 2018;43:1947-67. [PMID: 28929197 DOI: 10.1007/s00261-017-1298-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Ohira S, Kanayama N, Wada K, Ikawa T, Hirata T, Kishi N, Karino T, Washio H, Ueda Y, Miyazaki M, Koizumi M, Teshima T. Improvement of image quality and assessment of respiratory motion for hepatocellular carcinoma with portal vein tumor thrombosis using contrast-enhanced four-dimensional dual-energy computed tomography. PLoS One 2021;16:e0244079. [PMID: 33481820 DOI: 10.1371/journal.pone.0244079] [Reference Citation Analysis]
4 Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. J Hepatol 2017;67:173-83. [PMID: 28323121 DOI: 10.1016/j.jhep.2017.03.007] [Cited by in Crossref: 90] [Cited by in F6Publishing: 100] [Article Influence: 18.0] [Reference Citation Analysis]
5 Yu JI, Lee SJ, Lee J, Lim HY, Paik SW, Yoo GS, Choi C, Park HC. Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma. Cancer Med 2019;8:6986-94. [PMID: 31588679 DOI: 10.1002/cam4.2570] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
6 Wang W, Shen J, Wang C, Ren B, Zhu X, Ni C. Safety and Feasibility of Helical I-125 Seed Implants Combined with Transcatheter Arterial Chemoembolization in Hepatocellular Carcinomas with Main Portal Vein Tumor Thrombus. Cardiovasc Intervent Radiol 2019;42:1420-8. [DOI: 10.1007/s00270-019-02256-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kuo F, Cheng T, Cheng Y, Wu C, Wang C. Effectiveness of multimodality treatment for hepatocellular carcinoma patients with portal vein thrombosis: A real world experience. Adv in Digestive Med. [DOI: 10.1002/aid2.13275] [Reference Citation Analysis]
8 Cheng S, Chen M, Cai J; National Research Cooperative Group for Diagnosis and Treatment of Hepatocellular Carcinoma with Tumor Thrombus. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition. Oncotarget. 2017;8:8867-8876. [PMID: 27780939 DOI: 10.18632/oncotarget.12817] [Cited by in Crossref: 27] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
9 Choi C, Yoo GS, Cho WK, Park HC. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World J Gastroenterol 2019; 25(20): 2416-2429 [PMID: 31171886 DOI: 10.3748/wjg.v25.i20.2416] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 31] [Article Influence: 11.7] [Reference Citation Analysis]
10 Park JH, Kim HY, Lee A, Seo YK, Kim IH, Park ET, Kang MS, Park SJ, Park S. Enlightening the Immune Mechanism of the Abscopal Effect in a Murine HCC Model and Overcoming the Late Resistance With Anti-PD-L1. Int J Radiat Oncol Biol Phys 2021;110:510-20. [PMID: 33383126 DOI: 10.1016/j.ijrobp.2020.12.031] [Reference Citation Analysis]
11 Lu J, Zhang X, Zhong B, Lau WY, Madoff DC, Davidson JC, Qi X, Cheng S, Teng G. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology & Hepatology 2019;4:721-30. [DOI: 10.1016/s2468-1253(19)30178-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 12.3] [Reference Citation Analysis]
12 Yoo GS, Yu JI, Park HC, Hyun D, Jeong WK, Lim HY, Choi MS, Ha SY. Do Biliary Complications after Proton Beam Therapy for Perihilar Hepatocellular Carcinoma Matter? Cancers (Basel) 2020;12:E2395. [PMID: 32847035 DOI: 10.3390/cancers12092395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zhu Z, Wang X, Yuan K, Huang J, Zeng Y. Transarterial chemoembolization plus iodine-125 implantation for hepatocellular carcinoma: a systematic review and meta-analysis. HPB 2018;20:795-802. [DOI: 10.1016/j.hpb.2018.03.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
14 Wang C, Wang W, Shen J, Ren B, Zhu X, Ni C. Feasibility of Helical I-125 Seed Implant in the Portal Vein. Cardiovasc Intervent Radiol 2019;42:121-9. [DOI: 10.1007/s00270-018-2059-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Shui Y, Yu W, Ren X, Guo Y, Xu J, Ma T, Zhang B, Wu J, Li Q, Hu Q, Shen L, Bai X, Liang T, Wei Q. Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis. Radiat Oncol 2018;13:188. [PMID: 30253783 DOI: 10.1186/s13014-018-1136-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
16 Wang JC, Xia AL, Xu Y, Lu XJ. Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis. J Cell Physiol. 2019;234:1062-1070. [PMID: 30256409 DOI: 10.1002/jcp.27324] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
17 Sun N, Zhang J, Li B, Li A, Lv M, Zhang C. Favorable response to multimodal treatment in hepatocellular carcinoma with inferior vena cava and right atrial tumor thrombus and left adrenal gland metastasis: A case report and literature review. Medicine (Baltimore) 2021;100:e27987. [PMID: 34889243 DOI: 10.1097/MD.0000000000027987] [Reference Citation Analysis]
18 Li X, Guo W, Guo L, Lau WY, Ge N, Wang K, Cheng S. Should transarterial chemoembolization be given before or after intensity-modulated radiotherapy to treat patients with hepatocellular carcinoma with portal vein tumor thrombus? a propensity score matching study. Oncotarget 2018;9:24537-47. [PMID: 29849959 DOI: 10.18632/oncotarget.25224] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
19 Yoo GS, Yu JI, Park HC. Current role of proton beam therapy in patients with hepatocellular carcinoma. Int J Gastrointest Interv 2021;10:175-82. [DOI: 10.18528/ijgii210043] [Reference Citation Analysis]
20 Tao ZW, Cheng BQ, Zhou T, Gao YJ. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00229-0. [PMID: 34955380 DOI: 10.1016/j.hbpd.2021.12.004] [Reference Citation Analysis]
21 Makita Y, Murata S, Katou Y, Kikuchi K, Uejima H, Teratani M, Hoashi Y, Kenjo E, Matsumoto S, Nogami M, Otake K, Kawamata Y. Anti-tumor activity of KNTC2 siRNA in orthotopic tumor model mice of hepatocellular carcinoma. Biochem Biophys Res Commun 2017;493:800-6. [PMID: 28843857 DOI: 10.1016/j.bbrc.2017.08.088] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
22 Yoo GS, Yu JI, Cho S, Jung SH, Han Y, Park S, Oh Y, Lee B, Park HC, Lim DH, Choi MS, Won H. Comparison of clinical outcomes between passive scattering versus pencil-beam scanning proton beam therapy for hepatocellular carcinoma. Radiother Oncol 2020;146:187-93. [PMID: 32179362 DOI: 10.1016/j.radonc.2020.02.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
23 Yu JI, Park HC, Jung SH, Choi C, Shin SW, Cho SK, Sinn DH, Paik YH, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC, Sahinbas H, Paik SW. Combination treatment with transarterial chemoembolization, radiotherapy, and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumor thrombosis: Final results of a prospective phase II trial.Oncotarget. 2017;8:52651-52664. [PMID: 28881759 DOI: 10.18632/oncotarget.17072] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
24 Choi SH, Seong J. Strategic Application of Radiotherapy for Hepatocellular Carcinoma. Clin Mol Hepatol. 2018; Epub ahead of print. [PMID: 29439305 DOI: 10.3350/cmh.2017.0073] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
25 Yoo GS, Yu JI, Park HC. Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives. World J Gastroenterol 2018; 24(28): 3090-3100 [PMID: 30065555 DOI: 10.3748/wjg.v24.i28.3090] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
26 Li X, Ye Z, Lin S, Pang H. Predictive factors for survival following stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumour thrombosis and construction of a nomogram. BMC Cancer 2021;21:701. [PMID: 34126955 DOI: 10.1186/s12885-021-08469-1] [Reference Citation Analysis]
27 Cheng S, Chen M, Cai J, Sun J, Guo R, Bi X, Lau WY, Wu M. Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition). Liver Cancer 2020;9:28-40. [PMID: 32071907 DOI: 10.1159/000503685] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
28 Li JR, Wu MJ, Wang T, Tian M, Zhou G, Liu QX, Xiang XH, Zhang YQ. A prognostic score model for predicting the survival benefits of patients undergoing sorafenib plus transarterial chemoembolization for hepatocellular carcinoma with portal vein invasion. Abdom Radiol (NY) 2021;46:1967-76. [PMID: 33386450 DOI: 10.1007/s00261-020-02897-6] [Reference Citation Analysis]
29 Kaneko S, Tsuchiya K, Yasui Y, Inada K, Kirino S, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Takeguchi T, Takeguchi Y, Nagano T, Nakanishi H, Itakura J, Takahashi Y, Himeno Y, Hoshi A, Kurosaki M, Izumi N. Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis. Hepatol Res 2020;50:1375-85. [DOI: 10.1111/hepr.13567] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
30 Luo F, Li M, Ding J, Zheng S. The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Front Oncol 2021;11:635731. [PMID: 34631513 DOI: 10.3389/fonc.2021.635731] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Yoo GS, Ahn WG, Kim SY, Kang W, Choi C, Park HC. Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study. Clin Mol Hepatol 2021;27:144-56. [PMID: 33280350 DOI: 10.3350/cmh.2020.0095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Bai S, Wu Y, Yan Y, Li R, Kang H, Zhang J, Ma W, Gao Y, Hui B, Ma H, Zhang X, Ren J. Evaluation of the Efficacy and Toxicity of Radiotherapy for Type III-IV Portal Vein Tumor Thrombi. Technol Cancer Res Treat 2021;20:1533033821995286. [PMID: 33590809 DOI: 10.1177/1533033821995286] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Lin J, Jiang H, Yang W, Jiang N, Zheng Q, Huang N, Wang X, Li A, Huang J. Predictive factors of benefit from iodine-125 brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis. Brachytherapy. 2018;pii:S1538-4721(18)30424-0. [PMID: 30467014 DOI: 10.1016/j.brachy.2018.10.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]